Company Overview and News

Allianz Malaysia Q2 net profit rises to RM90mil

PETALING JAYA: Allianz Malaysia Bhd ’s (AMB) net profit for its second quarter ended June 30, 2018 increased 35% to RM89.87mil from RM66.48mil in the previous corresponding period, mainly due to lower management expenses ratio from lower impairment of insurance receivables.
1163 BSMAF 1818

Utusan, Petrol One, Eita Resources, Gadang, Dayang Enterprise, PetDag, Allianz, United Plantations, E&O, Velesto Energy, Amway and Rex Industry

12h theedgemarkets
KUALA LUMPUR (Aug 20): Based on corporate announcements and news flow today, companies in focus on Tuesday (Aug 21) may include the following: Utusan Melayu (Malaysia) Bhd, Petrol One Resources Bhd, Eita Resources Bhd, Gadang Holdings Bhd, Dayang Enterprise Holdings Bhd, Petronas Dagangan Bhd, Allianz Malaysia Bhd, United Plantations Bhd, Eastern and Oriental Bhd (E&O), Velesto Energy Bhd, Amway (Malaysia) Holdings Bhd and Rex Industry Bhd.
9261 UPBMF 5681 5141 7027 1163 2089 5754 5209 5208 9946 BSMAF 1818

Allianz Malaysia Q2 net profit rises to RM89.87m

16h malaymail
KUALA LUMPUR, Aug 20 — Allianz Malaysia Bhd’s net profit rose to RM89.87 million in the second quarter ended June 30, 2018 (Q2) from RM66.48 million a year ago, due mainly to higher contribution from general insurance and life insurance segments.
1163 BSMAF 1818

Allianz posts 35% jump in 2Q net profit

18h theedgemarkets
KUALA LUMPUR (Aug 20): Allianz Malaysia Bhd's net profit jumped 35.2% year-on-year in its second quarter ended June 30, 2018 (2QFY18) to RM89.87 million from RM66.48 million, as the composite insurer's revenue strengthens.

Foreign insurers given more flexibility to divest their stakes, deadline to depend on bilateral pact

2018-08-17 theedgemarkets
KUALA LUMPUR (Aug 17): Foreign insurers in Malaysia will be given more flexibility to divest their stakes, and the deadline for the divestments will now depend on the bilateral agreement between the insurance companies and Bank Negara Malaysia (BNM).
1058 ALIZF AZSEY 1163 BSMAF 1818

‘Nothing on the table’ for general insurance sale

2018-07-28 - 1
Market talk of AMMB Holdings Bhd ’s (AmBank) plan to sell off its general insurance business, AmGeneral Insurance Bhd, has been gaining traction in recent weeks with some foreign and even local insurance companies said to be potential suitors.

KLCI pares loss, claws above 1,680-level

2018-07-11 theedgemarkets
KUALA LUMPUR (July 11): The FBM KLCI pared some of its losses at midday break today, and moved above the 1,680-point level.
PBLOF 7113 BATS TPGVF 4162 1295 7153 9334 5199 3204 5347 3301 7668 TNABY AXXTF HIPEF GEBHF SPMXF 1163 0131 TGLVY SPMXY 0026 6888 1899 TNABF

KLCI falls 0.37%, tracks region as U.S. decides more tariffs on China

2018-07-11 theedgemarkets
KUALA LUMPUR (July 11): The FBM KLCI fell 0.37% at mid-morning today as the U.S. re-ignited fears of a larger scale trade war with China after announcing it would impose added tariffs on Chinese imports.
7113 5681 TPGVF BATS 4162 1163 7153 TGLVY 7668 6888 AXXTF BSMAF 1818

KLCI reverses loss at 11th hour after day-long pressure from trade war woes

2018-07-05 theedgemarkets
KUALA LUMPUR (July 5): The FBM KLCI reversed its losses at 11th hour today, after going through much pressure as investors were concern about the imminent trade war between the US and China.
2836 1163

KLCI turns negative as trade war anxiety weighs

2018-07-05 theedgemarkets
KUALA LUMPUR (July 5): The FBM KLCI turned negative at midday break today in tandem with most regional markets, on investors’ anxiety ahead of the Friday deadline for additional U.S. tariffs on Chinese products.
PBLOF MLYBY SPMXF MLYNF UPBMF BATS 4162 1163 1295 2089 9334 0023 1155 5139 SPMXY 3883 3301 0900 0026 1899 2836 3719

Telekom Malaysia, Axiata lift KLCI despite shaky regional markets

2018-07-04 theedgemarkets
KUALA LUMPUR (July 4): The FBM KLCI rose at midday break today, lifted by gains at select index-linked blue chips, including Telekom Malaysia Bhd and Axiata Group Bhd, against the backdrop of weaker regional markets.
HLFBF 7084 1082 5031 BATS 4162 1163 0023 KLKBY 2445 4588 4863 5347 3867 0037 0026 TNABY 6888 5819 AXXTF MYTEF TNABF 3719

KLCI pares gains in line with shaky regional markets

2018-07-04 theedgemarkets
KUALA LUMPUR (July 4): The FBM KLCI pared some of its gains at mid-morning today in line with the shaky regional markets, as mounting worries of an escalating U.S.-China trade spat kept global investors on tenterhooks.
7084 4065 BATS 4162 1163 7374 7055 0120 KLKBY 5139 2445 4863 3867 0037 0900 0026 MYTEF 3719

KLCI poised to extend losses, down 0.43% tracking region

2018-07-03 theedgemarkets
KUALA LUMPUR (July 3): The FBM KLCI looked set to extend its losses today in line with the turbulent regional markets, as it fell 0.43% at the midday break.
HLFBF 5270 UPBMF 8621 7036 1082 4197 5681 BATS 4162 1163 2089 5199 KLKBY 2445 5347 3867 SMEBF TNABY TNABF HIPEF 3719

KLCI reverses gains, falls 0.63% as regional markets slip

2018-07-03 theedgemarkets
KUALA LUMPUR (July 3): The FBM KLCI reversed its earlier gains and fell 0.63% at mid-morning today, as Asian markets slipped.
4006 KLKBY 5139 2445 0900 6888 7036 5681 AXXTF 1163 ORHLF 7055

KLCI pares loss, down 0.78% as sentiment stays tepid

2018-06-18 theedgemarkets
KUALA LUMPUR (June 18): The FBM KLCI pared some of its losses at the midday break and was down 0.78%, with tepid sentiment tracking losses at the regional markets.
APEXF 7251 7090 7113 BATS TPGVF 4162 3034 KLKBY 5226 5347 3301 TNABY AXXTF HRGHY 5681 2291 1163 5168 TGLVY 2445 1996 6888 5819 TNABF

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="